We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
8 own
13 watching
Current Price
$0.45
$0
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
19.11M
52-Week High
5.76
52-Week Low
0.375
Average Volume
0.04M
Dividend Yield
--
P/E Ratio
--
Market Capitalization19.11M
52-Week High5.76
52-Week Low0.375
Average Volume0.04M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
9days ago
HC Wainwright cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports. HC Wainwright also issued estimates for Neoleukin Therapeutics Q2 2023 earnings at ($0.17) EPS...
Globe Newswire
26days ago
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH...
Zolmax
6 months ago
Zacks Investment Research cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in ...
Globe Newswire
7 months ago
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company ...
Benzinga
8 months ago
On Thursday, 112 stocks made new 52-week lows. read more...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.45
$0
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00